Erythema Infectiosum: A Narrative Review


Cite item

Full Text

Abstract

Background:Erythema infectiosum occurs worldwide. School-aged children are most often affected. Since the diagnosis is mainly clinical, physicians should be well-versed in the clini-cal manifestations of erythema infectiosum to avoid misdiagnosis, unnecessary investigations, and mismanagement of the disease.

Objective:The purpose of this article is to familiarize physicians with the wide spectrum of clinical manifestations and complications of erythema infectiosum associated with parvovirus B19 infection.

Methods:A search was conducted in July 2022 in PubMed Clinical Queries using the key terms \"Erythema infectiosum\" OR "Fifth disease" OR "Slapped cheek disease" OR "Parvovirus B19". The search strategy included all clinical trials, observational studies, and reviews published within the past 10 years. Only papers published in the English literature were included in this review. The information retrieved from the above search was used in the compilation of the present article.

Results:Erythema infectiosum is a common exanthematous illness of childhood caused by parvovirus B19. Parvovirus B19 spreads mainly by respiratory tract secretions and, to a lesser extent, the saliva of infected individuals. Children between 4 and 10 years of age are most often affected. The incubation period is usually 4 to 14 days. Prodromal symptoms are usually mild and consist of low-grade fever, headache, malaise, and myalgia. The rash typically evolves in 3 stages. The initial stage is an erythematous rash on the cheeks, with a characteristic "slapped cheek" appearance. In the second stage, the rash spreads concurrently or quickly to the trunk, extremities, and buttocks as diffuse macular erythema. The rash tends to be more intense on extensor surfaces. The palms and soles are typically spared. Central clearing of the rash results in a characteristic lacy or reticulated appearance. The rash usually resolves spontaneously within three weeks without sequelae. The third stage is characterized by evanescence and recrudescence. In adults, the rash is less pronounced than that in children and is often atypical. Only approximately 20% of affected adults have an erythematous rash on the face. In adults, the rash is more frequently found on the legs, followed by the trunk, and arms. A reticulated or lacy erythema is noted in 80% of cases which helps to distinguish erythema infectiosum from other exanthems. Pruritus is noted in approximately 50% of cases. The diagnosis is mainly clinical. The many manifestations of parvovirus B19 infection can pose a diagnostic challenge even to the best diagnostician. Complications include arthritis, arthralgia, and transient aplastic crisis. In most cases, treatment is symptomatic and supportive. When parvovirus B19 infection occurs in pregnant women, hydrops fetalis becomes a real concern.

Conclusion:Erythema infectiosum, the most common clinical manifestation of parvovirus B19 in-fection, is characterized by a "slapped cheek" appearance on the face and lacy exanthem on the trunk and extremities. Parvovirus B19 infection is associated with a wide spectrum of clinical mani-festations. Physicians should be aware of potential complications and conditions associated with parvovirus B19 infection, especially in individuals who are immunocompromised, chronically ane-mic, or pregnant.

About the authors

Alexander Leung

Department of Pediatrics, The University of Calgary, Alberta Children’s Hospital

Author for correspondence.
Email: info@benthamscience.net

Joseph Lam

Department of Pediatrics and Department of Dermatology and Skin Sciences, University of British Columbia

Email: info@benthamscience.net

Benjamin Barankin

Department of Dermatology,, Toronto Dermatology Centre

Email: info@benthamscience.net

Kin Leong

Pediatric Institute, Kuala Lumpur General Hospital

Email: info@benthamscience.net

Kam Hon

Department of Paediatrics,, The Chinese University of Hong Kong

Email: info@benthamscience.net

References

  1. Macri A, Crane JS. ParvovirusesStatPearls. Treasure Island (FL): StatPearls Publishing 2022.
  2. Mende M, Sockel K. Parvovirus B19 Infection. N Engl J Med 2018; 379(24): 2361. doi: 10.1056/NEJMicm1807156 PMID: 30575471
  3. Young NS, Brown KE. Parvovirus B19. N Engl J Med 2004; 350(6): 586-97. doi: 10.1056/NEJMra030840 PMID: 14762186
  4. Magro CM, Dawood MR, Crowson AN. The cutaneous manifestations of humanparvovirus B19 infection. Hum Pathol 2000; 31(4): 488-97. doi: 10.1053/hp.2000.6714 PMID: 10821497
  5. Rogo LD, Mokhtari-Azad T, Kabir MH, Rezaei F. Human parvovirus B19: A review. Acta Virol 2014; 58(3): 199-213. doi: 10.4149/av_2014_03_199 PMID: 25283854
  6. Leung AK, Robson WL. Erythema infectiosum (fifth disease). Consultant Pediatrician 2006; 5: 366-70. doi: 10.25270/cfp.2006.06.00001
  7. Cossart YE, Field AM, Cant B, Widdows D. Parvovirus-like particles in human sera. Lancet 1975; 1(7898): 72-3. doi: 10.1016/S0140-6736(75)91074-0
  8. Landry ML. Parvovirus B19. Microbiol Spectr 2016; 4(3): 4-34. doi: 10.1128/microbiolspec.DMIH2-0008-2015 PMID: 27337440
  9. Anderson MJ, Jones SE, Fisher-Hoch SP, et al. Human parvovirus, the cause of erythema infectiosum (fifth disease)? Lancet 1983; 321(8338): 1378. doi: 10.1016/S0140-6736(83)92152-9 PMID: 6134148
  10. Jordan JA. Treatment and prevention of parvovirus B19 infection. UpToDate, Inc 2022.
  11. Koch WC. Fifth (human parvovirus) and sixth (herpesvirus 6) diseases. Curr Opin Infect Dis 2001; 14(3): 343-56. doi: 10.1097/00001432-200106000-00016 PMID: 11964854
  12. Jordan JA. Virology, epidemiology, and pathogenesis of parvovirus B19 infection. UpToDate
  13. Schwarz TF, Wiersbitzky S, Pambor M. Detection of parvovirus B19 in a skin biopsy of a patient with erythema infectiosum. J Med Virol 1994; 43(2): 171-4. doi: 10.1002/jmv.1890430214 PMID: 8083666
  14. Takahashi Y, Murai C, Shibata S, et al. Human parvovirus B19 as a causative agent for rheumatoid arthritis. Proc Natl Acad Sci USA 1998; 95(14): 8227-32. doi: 10.1073/pnas.95.14.8227 PMID: 9653169
  15. Anderson MJ, Higgins PG, Davis LR, et al. Experimental parvoviral infection in humans. J Infect Dis 1985; 152(2): 257-65. doi: 10.1093/infdis/152.2.257 PMID: 2993431
  16. Riley LE, Fernandes CJ. Parvovirus B19 infection during pregnancy. UpToDate
  17. Huerta-Brogeras M, Avilés Izquierdo JA, Hernanz Hermosa JM, Lázaro-Ochaita P, Longo-Imedio MI. Petechial exanthem in "bathing trunk" distribution caused by parvovirus B19 infection. Pediatr Dermatol 2005; 22(5): 430-3. doi: 10.1111/j.1525-1470.2005.00109.x PMID: 16190994
  18. Young N, Mortimer P. Viruses and bone marrow failure. Blood 1984; 63(4): 729-37. doi: 10.1182/blood.V63.4.729.729 PMID: 6322884
  19. Brown KE, Anderson SM, Young NS. Erythrocyte P antigen: Cellular receptor for B19 parvovirus. Science 1993; 262(5130): 114-7. doi: 10.1126/science.8211117 PMID: 8211117
  20. Jordan JA, DeLoia JA. Globoside expression within the human placenta. Placenta 1999; 20(1): 103-8. doi: 10.1053/plac.1998.0353 PMID: 9950151
  21. Frydenberg A, Starr M. Slapped cheek disease. How it affects children and pregnant women. Aust Fam Physician 2003; 32(8): 589-92. PMID: 12973864
  22. Jordan JA. Identification of human parvovirus B19 infection in idiopathic nonimmune hydrops fetalis. Am J Obstet Gynecol 1996; 174(1): 37-42. doi: 10.1016/S0002-9378(96)70370-8 PMID: 8572031
  23. Mandel ED. Erythema infectiosum: Recognizing the many faces of fifth disease. JAAPA 2009; 22(6): 42-6. doi: 10.1097/01720610-200906000-00009 PMID: 19601449
  24. McOmish F, Yap PL, Jordan A, Hart H, Cohen BJ, Simmonds P. Detection of parvovirus B19 in donated blood: A model system for screening by polymerase chain reaction. J Clin Microbiol 1993; 31(2): 323-8. doi: 10.1128/jcm.31.2.323-328.1993 PMID: 8432819
  25. Saldanha J, Minor P. Detection of human parvovirus B19 DNA in plasma pools and blood products derived from these pools: Implica-tions for efficiency and consistency of removal of B19 DNA during manufacture. Br J Haematol 1996; 93(3): 714-9. doi: 10.1046/j.1365-2141.1996.d01-1679.x PMID: 8652400
  26. Vafaie J, Schwartz RA. Erythema Infectiosum. J Cutan Med Surg 2005; 9(4): 159-61. doi: 10.1177/120347540500900401 PMID: 16502203
  27. Yoto Y, Kudoh T, Haseyama K, et al. Incidence of human parvovirus B19 DNA detection in blood donors. Br J Haematol 1995; 91(4): 1017-8. doi: 10.1111/j.1365-2141.1995.tb05427.x PMID: 8547113
  28. Kostolansky S, Waymack JR. Erythema infectiosum. Treasure Island, FL: StatPearls Publishing. StatPearls 2021.
  29. Ramdass P, Mullick S, Farber HF. Viral skin diseases. Prim Care 2015; 42(4): 517-67. doi: 10.1016/j.pop.2015.08.006 PMID: 26612372
  30. Luo J, Zhang J, Lai W, et al. Disseminated human parvovirus B19 infection induced multiple organ dysfunction syndrome in an adult patient with alcoholic hepatitis complicated by hemolytic anemia: A case report and literature review. Front Immunol 2021; 12742990. doi: 10.3389/fimmu.2021.742990 PMID: 34970255
  31. Prćić S, Gajinov Z, Zrnić B, Radulović A, Matić M, Djuran V. Epidemiological and clinical features of erythema infectiosum in children in Novi Sad from 2000 to 2009. Vojnosanit Pregl 2013; 70(12): 1081-4. doi: 10.2298/VSP110607026P PMID: 24450250
  32. Cohen BJ, Buckley MM. The prevalence of antibody to human parvovirus B 19 in England and Wales. J Med Microbiol 1988; 25(2): 151-3. doi: 10.1099/00222615-25-2-151 PMID: 3339634
  33. American Academy of Pediatrics. Parvovirus B19 (erythema infectiosum, fifth disease).Red Book: 2021-2024 Report of the Committee on Infectious Diseases. 32nd ed. Kimberlin DW, Barnett ED, Lynfield R, Swayer MH, Eds. Itasca, IL: American Academy of Pediatrics 2022; pp. 562-6.
  34. Woolf AD, Campion GV, Chishick A, et al. Clinical manifestations of human parvovirus B19 in adults. Arch Intern Med 1989; 149(5): 1153-6. doi: 10.1001/archinte.1989.00390050111022 PMID: 2541666
  35. Gillespie SM, Cartter ML, Asch S, et al. Occupational risk of human parvovirus B19 infection for school and day-care personnel during an outbreak of erythema infectiosum. JAMA 1990; 263(15): 2061-5. doi: 10.1001/jama.1990.03440150069028 PMID: 2157074
  36. Jordan JA. Clinical manifestations and diagnosis of parvovirus B19 infection. UpToDate
  37. Weir E. Parvovirus B19 infection: Fifth disease and more. CMAJ 2005; 172(6): 743. doi: 10.1503/cmaj.045293 PMID: 15767606
  38. Veraldi S, Rizzitelli G. Erythematous exanthem associated with primary infection by human parvovirus B19. Int J Dermatol 1995; 34(2): 119. doi: 10.1111/j.1365-4362.1995.tb03594.x PMID: 7737770
  39. Sachan D. Erythema infectiosum rash. Indian Pediatr 2011; 48(4): 338. PMID: 21532111
  40. Allmon A, Deane K, Martin KL. Common skin rashes in children. Am Fam Physician 2015; 92(3): 211-6. PMID: 26280141
  41. Mage V, Lipsker D, Barbarot S, et al. Different patterns of skin manifestations associated with parvovirus B19 primary infection in adults. J Am Acad Dermatol 2014; 71(1): 62-9. doi: 10.1016/j.jaad.2014.02.044 PMID: 24726401
  42. Molenaar-de Backer MWA, Russcher A, Kroes ACM, Koppelman MHGM, Lanfermeijer M, Zaaijer HL. Detection of parvovirus B19 DNA in blood: Viruses or DNA remnants? J Clin Virol 2016; 84: 19-23. doi: 10.1016/j.jcv.2016.09.004 PMID: 27664778
  43. Serjeant GR, Serjeant BE, Thomas PW, Anderson MJ, Patou G, Pattison JR. Human parvovirus infection in homozygous sickle cell disease. Lancet 1993; 341(8855): 1237-40. doi: 10.1016/0140-6736(93)91145-C PMID: 8098391
  44. Alcántara González J, Boixeda P, Truchuelo Díez MT, Fleta Asín B. Keratosis pilaris rubra and keratosis pilaris atrophicans faciei treated with pulsed dye laser: Report of 10 cases. J Eur Acad Dermatol Venereol 2011; 25(6): 710-4. doi: 10.1111/j.1468-3083.2010.03772.x PMID: 20569297
  45. Alexiades-Armenakas M. Tumid lupus erythematosus. Dermatol Online J 2001; 7(2): 14. doi: 10.5070/D31K03Z1TV PMID: 12165230
  46. Arias AF, Diaz A, Erdem G. Tinea faciei caused by Trichophyton benhamiae in a child. Pediatr Dermatol 2021; 38(2): 520-1. doi: 10.1111/pde.14486 PMID: 33336837
  47. Callen J. Approach to the patient with facial erythema. UpToDate 2023.
  48. Cox B, Levent F. Hand, foot, and mouth disease. JAMA 2018; 320(23): 2492. doi: 10.1001/jama.2018.17288 PMID: 30561482
  49. Esposito S, Principi N. Hand, foot and mouth disease: Current knowledge on clinical manifestations, epidemiology, aetiology and prevention. Eur J Clin Microbiol Infect Dis 2018; 37(3): 391-8. doi: 10.1007/s10096-018-3206-x PMID: 29411190
  50. Grosshans EM. The red face: Erysipelas. Clin Dermatol 1993; 11(2): 307-13. doi: 10.1016/0738-081X(93)90067-M PMID: 8348445
  51. Jin H, Zhang G, Zhou Y, Chang C, Lu Q. Old lines tell new tales: Blaschko linear lupus erythematosis. Autoimmun Rev 2016; 15(4): 291-306. doi: 10.1016/j.autrev.2015.11.014 PMID: 26678347
  52. Leung AKC, Rafaat M. Eruption associated with amoxicillin in a patient with infectious mononucleosis. Int J Dermatol 2003; 42(7): 553-5. doi: 10.1046/j.1365-4362.2003.01699_1.x PMID: 12839608
  53. Leung AKC, Kellner JD. Group A β-hemolytic streptococcal pharyngitis in children. Adv Ther 2004; 21(5): 277-87. doi: 10.1007/BF02850032 PMID: 15727397
  54. Leung TNH, Hon KL, Leung AKC, Group A, Group A. Streptococcus disease in Hong Kong children: An overview. Hong Kong Med J 2018; 24(6): 593-601. doi: 10.12809/hkmj187275 PMID: 30416105
  55. Leung AKC, Hon KL, Leong KF, Sergi CM. Measles: A disease often forgotten but not gone. Hong Kong Med J 2018; 24(5): 512-20. doi: 10.12809/hkmj187470 PMID: 30245481
  56. Leung AKC, Hon KL, Leong KF. Rubella (German measles) revisited. Hong Kong Med J 2019; 25(2): 134-41. doi: 10.12809/hkmj187785 PMID: 30967519
  57. Leung AKC, Lam JM, Alobaida S, Leong KF, Wong AHC. Juvenile dermatomyositis: Advances in pathogenesis, assessment, and management. Curr Pediatr Rev 2021; 17(4): 273-87. doi: 10.2174/1573396317666210426105045 PMID: 33902423
  58. Leung AKC, Leong KF, Lam JM. Asymptomatic linear erythematous plaques following the lines of Blaschko on the cheek. Paediatr Child Health 2022; 27(3): 136-7. doi: 10.1093/pch/pxab113 PMID: 35712038
  59. Lopez FA, Sanders CV. Fever and rash in the immunocompetent patient. UpToDate
  60. Maliyar K, Abdulla SJ. Dermatology: How to manage rosacea in skin of colour. Drugs Context 2022; 11: 1-9. doi: 10.7573/dic.2021-11-1 PMID: 35720055
  61. Papazoglou A, Mantadakis E. Fig tree leaves phytophotodermatitis. J Pediatr 2021; 239: 244-5. doi: 10.1016/j.jpeds.2021.08.029 PMID: 34428434
  62. Rizzolo D, McWeeney M. A toddler’s fever and rash. JAAPA 2013; 26(7): 11-2. doi: 10.1097/01.JAA.0000431514.97948.fd PMID: 23923281
  63. Tsang V, Leung AKC, Lam JM. Cutaneous lupus erythematosus in children. Curr Pediatr Rev 2021; 17(2): 103-10. doi: 10.2174/1573396317666210224144416 PMID: 33655840
  64. Cervero R. Systemic lupus erythematosus criteria nowadays. Med Clin 2022; 159(4): 187-8. doi: 10.1016/j.medcle.2022.04.008
  65. Lazar S, Kahlenberg JM. Systemic Lupus erythematosus: New diagnostic and therapeutic approaches. Annu Rev Med 2022; 74: 339-52. doi: 10.1146/annurev-med-043021-032611 PMID: 35804480
  66. Rixe N, Tavarez MM. Serum sickness StatPearls. Treasure Island, FL: StatPearls Publishing 2022.
  67. Sahba S, Huurnink A, Van den Berg JM, Tuitert B, Vastert SJ, Ten Tusscher GW. Systemic Juvenile Idiopathic Arthritis in two children; case report on clinical course, challenges in diagnosis and the role of FDG‐PET/CT‐scan. Clin Case Rep 2022; 10(6): e05900. doi: 10.1002/ccr3.5900 PMID: 35734189
  68. Tjahjono L, Czaja R, Lalor L, Hasse-Rupp B, Wanat KA. Persistent papules and plaques in systemic juvenile idiopathic arthritis. Pediatr Dermatol 2022; 39(4): 616-8. doi: 10.1111/pde.15029 PMID: 35560434
  69. Servey JT, Reamy BV, Hodge J. Clinical presentations of parvovirus B19 infection. Am Fam Physician 2007; 75(3): 373-6. PMID: 17304869
  70. Tello-Winniczuk N, Díaz-Jouanen E, Díaz-Borjón A. Parvovirus B19-associated arthritis: Report on a community outbreak. J Clin Rheumatol 2011; 17(8): 449-50. doi: 10.1097/RHU.0b013e31823abf1a PMID: 22089996
  71. Corcoran A, Doyle S. Advances in the biology, diagnosis and host–pathogen interactions of parvovirus B19. J Med Microbiol 2004; 53(6): 459-75. doi: 10.1099/jmm.0.05485-0 PMID: 15150324
  72. Neely G, Cabrera R, Hojman L. Parvovirus B19: A DNA virus associated with multiple cutaneous manifestations. Rev Chilena Infectol 2018; 35(5): 518-30. doi: 10.4067/s0716-10182018000500518 PMID: 30724999
  73. Scroggie DA, Carpenter MT, Cooper RI, Higgs JB. Parvovirus arthropathy outbreak in southwestern United States. J Rheumatol 2000; 27(10): 2444-8. PMID: 11036842
  74. Tiwari V, Bergman MJ. Viral arthritisStatPearls. Treasure Island, FL: StatPearls Publishing 2022.
  75. Alexander V, Das S, Mangan A, Iyadurai R. Acute parvovirus B19 infection presenting as rheumatoid arthritis mimic. J Family Med Prim Care 2019; 8(3): 1257-9. doi: 10.4103/jfmpc.jfmpc_25_19 PMID: 31041286
  76. Speyer I, Breedveld FC, Dijkmans BA. Human parvovirus B19 infection is not followed by inflammatory joint disease during long term follow-up. A retrospective study of 54 patients. Clin Exp Rheumatol 1998; 16(5): 576-8. PMID: 9779306
  77. Borsato ML, Bruniera P, Cusato MP, Spewien KE, Durigon EL, Toporovski J. Aplastic crisis in sickle cell anemia induced by parvovírus B19. J Pediatr 2000; 76(6): 458-60. doi: 10.2223/JPED.94 PMID: 14647635
  78. Florea AV, Ionescu DN, Melhem MF. Parvovirus B19 infection in the immunocompromised host. Arch Pathol Lab Med 2007; 131(5): 799-804. doi: 10.5858/2007-131-799-PBIITI PMID: 17488170
  79. Grohall SJ, Colon AA, Churosh JL, Bryant R III, Zangwill SD. Parvovirus: From fifth disease to heart transplant. J Pediatr Health Care 2022; 36(2): 165-9. doi: 10.1016/j.pedhc.2021.05.006 PMID: 34218967
  80. Barah F, Vallely PJ, Cleator GM, Kerr JR. Neurological manifestations of human parvovirus B19 infection. Rev Med Virol 2003; 13(3): 185-99. doi: 10.1002/rmv.388 PMID: 12740833
  81. Boeck K, Mempel M, Schmidt T, Abeck D. Gianotti-Crosti syndrome: Clinical, serologic, and therapeutic data from nine children. Cutis 1998; 62(6): 271-4. PMID: 9878981
  82. Douvoyiannis M, Litman N, Goldman DL. Neurologic manifestations associated with parvovirus B19 infection. Clin Infect Dis 2009; 48(12): 1713-23. doi: 10.1086/599042 PMID: 19441978
  83. Dubois A, Thellier S, Wierzbicka-Hainaut E, Pierre F, Anyfantakis V, Guillet G. Two cases of baboon-like exanthema in primary parvovi-rus B19 infection. Ann Dermatol Venereol 2010; 137(11): 709-12. doi: 10.1016/j.annder.2010.06.023 PMID: 21074654
  84. Esmel-Vilomara R, Dolader P, Izquierdo-Blasco J, et al. Parvovirus B19 myocarditis in children: A diagnostic and therapeutic approach. Eur J Pediatr 2022; 181(5): 2045-53. doi: 10.1007/s00431-022-04406-x PMID: 35138467
  85. Ferrari B, Díaz MS, López M, Larralde M. Unusual skin manifestations associated with parvovirus B19 primary infection in children. Pediatr Dermatol 2018; 35(6): e341-4. doi: 10.1111/pde.13623 PMID: 30230024
  86. Furukawa M, Kaji K, Masuda H, et al. Severe Aplastic anemia following parvovirus B19-associated acute hepatitis. Case Reports Hepatol 2017; 2017: 1-5. doi: 10.1155/2017/1359486 PMID: 28512588
  87. Grilli R, Izquierdo MJ, Fariña MC, et al. Papular-purpuric "gloves and socks" syndrome: Polymerase chain reaction demonstration of parvovirus B19 DNA in cutaneous lesions and sera. J Am Acad Dermatol 1999; 41(5): 793-6. doi: 10.1016/S0190-9622(99)70027-7 PMID: 10534650
  88. Hatakka A, Klein J, He R, Piper J, Tam E, Walkty A. Acute hepatitis as a manifestation of parvovirus B19 infection. J Clin Microbiol 2011; 49(9): 3422-4. doi: 10.1128/JCM.00575-11 PMID: 21734024
  89. Kellermayer R, Faden H, Grossi M. Clinical presentation of parvovirus B19 infection in children with aplastic crisis. Pediatr Infect Dis J 2003; 22(12): 1100-1. doi: 10.1097/01.inf.0000101783.73240.4a PMID: 14688575
  90. Keramari S, Poutoglidis A, Chatzis S, Keramaris M, Savopoulos C, Kaiafa G. Parvovirus B19-associated myocarditis: A literature review of pediatric cases. Cureus 2022; 14(1): e21726. doi: 10.7759/cureus.21726 PMID: 35251800
  91. Kishore J, Singh J. Detection of parvovirus B19 in a case of erythema infectiosum with myositis. Indian Pediatr 2006; 43(9): 814-7. PMID: 17033121
  92. Koliou M, Karaoli E, Soteriades ES, Pavlides S, Bashiardes S, Christodoulou C. Acute hepatitis and myositis associated with Erythema infectiosum by Parvovirus B19 in an adolescent. BMC Pediatr 2014; 14(1): 6. doi: 10.1186/1471-2431-14-6 PMID: 24410941
  93. Kreuter A, Koushk Jalali B, Tigges C, Silling S, Lehmann P, Wieland U. Juvenile spring eruption associated with parvovirus B19 infection. JAMA Dermatol 2018; 154(11): 1356-7. doi: 10.1001/jamadermatol.2018.2932 PMID: 30267044
  94. Kühl U, Rohde M, Lassner D, Gross UM, Escher F, Schultheiss HP. miRNA as activity markers in Parvo B19 associated heart disease. Herz 2012; 37(6): 637-43. doi: 10.1007/s00059-012-3656-3 PMID: 22872003
  95. Leung AKC, Barankin B. Unilateral laterothoracic exanthem. J Pediatr 2015; 167(3): 775. doi: 10.1016/j.jpeds.2015.06.042 PMID: 26187001
  96. Leventhal LJ, Naides SJ, Freundlich B. Fibromyalgia and parvovirus infection. Arthritis Rheum 1991; 34(10): 1319-24. doi: 10.1002/art.1780341018 PMID: 1657005
  97. Naciute M, Mieliauskaite D, Rugiene R, et al. Frequency and significance of parvovirus B19 infection in patients with rheumatoid arthritis. J Gen Virol 2016; 97(12): 3302-12. doi: 10.1099/jgv.0.000621 PMID: 27902343
  98. Pardi DS, Romero Y, Mertz LE, Douglas DD. Hepatitis-associated aplastic anemia and acute parvovirus B19 infection: A report of two cases and a review of the literature. Am J Gastroenterol 1998; 93(3): 468-70. doi: 10.1111/j.1572-0241.1998.468_1.x PMID: 9517662
  99. Pinho JRR, Alves VAF, Vieira AF, et al. Detection of human parvovirus B19 in a patient with hepatitis. Braz J Med Biol Res 2001; 34(9): 1131-8. doi: 10.1590/S0100-879X2001000900005 PMID: 11514836
  100. Sequeira J, Calado A, Dias M, Manita M. Parvovirus B19 infection associated with hemolytic anemia and cranial polyneuropathy. J Neurovirol 2017; 23(5): 786-8. doi: 10.1007/s13365-017-0562-8 PMID: 28831691
  101. Takeda S, Takaeda C, Takazakura E, Haratake J. Renal involvement induced by human parvovirus B19 infection. Nephron J 2001; 89(3): 280-5. doi: 10.1159/000046086 PMID: 11598390
  102. Zou Q, Chen P, Chen J, et al. Multisystem involvement induced by human parvovirus B19 infection in a non-immunosuppressed adult: A case report. Front Med 2022; 9808205. doi: 10.3389/fmed.2022.808205 PMID: 35492345
  103. Aktepe OC, Yetgin S, Olcay L, Özbek N. Human parvovirus B19 associated with idiopathic thrombocytopenic purpura. Pediatr Hematol Oncol 2004; 21(5): 421-6. doi: 10.1080/08880010490457141 PMID: 15205085
  104. Heegaard ED, Eiskjaer H, Baandrup U, Hornsleth A. Parvovirus B19 infection associated with myocarditis following adult cardiac transplantation. Scand J Infect Dis 1998; 30(6): 607-9. doi: 10.1080/00365549850161188 PMID: 10225391
  105. Finkel TH, Leung DYM, Harbeck RJ, et al. Chronic parvovirus B19 infection and systemic necrotising vasculitis: Opportunistic infection or aetiological agent? Lancet 1994; 343(8908): 1255-8. doi: 10.1016/S0140-6736(94)92152-0 PMID: 7910276
  106. Waldman M, Marshall V, Whitby D, Kopp JB. Viruses and kidney disease: Beyond HIV. Semin Nephrol 2008; 28(6): 595-607. doi: 10.1016/j.semnephrol.2008.08.010 PMID: 19013331
  107. Staroselsky A, Klieger-Grossmann C, Garcia-Bournissen F, Koren G. Exposure to fifth disease in pregnancy. Can Fam Physician 2009; 55(12): 1195-8. PMID: 20008596
  108. Anand A, Gray ES, Brown T, Clewley JP, Cohen BJ. Human parvovirus infection in pregnancy and hydrops fetalis. N Engl J Med 1987; 316(4): 183-6. doi: 10.1056/NEJM198701223160403 PMID: 3025725
  109. Kielaite D, Paliulyte V. Parvovirus (B19) infection during pregnancy: Possible effect on the course of pregnancy and rare fetal outcomes. A case report and literature review. Medicina 2022; 58(5): 664. doi: 10.3390/medicina58050664 PMID: 35630081
  110. Kontomanolis EN, Fasoulakis Z. Hydrops fetalis and the Parvovirus B-19. Curr Pediatr Rev 2018; 14(4): 239-52. doi: 10.2174/1573396314666180820154340 PMID: 30124157
  111. McCarter-Spaulding D. Parvovirus B19 in Pregnancy. J Obstet Gynecol Neonatal Nurs 2002; 31(1): 107-12. doi: 10.1111/j.1552-6909.2002.tb00029.x PMID: 11843014
  112. Petrikovsky BM, Baker D, Schneider E. Fetal hydrops secondary to human parvovirus infection in early pregnancy. Prenat Diagn 1996; 16(4): 342-4. doi: 10.1002/(SICI)1097-0223(199604)16:43.0.CO;2-F PMID: 8734809
  113. Schwarz T, Roggendorf M, Hottenträger B, et al. Human parvovirus B19 infection in pregnancy. Lancet 1988; 332(8610): 566-7. doi: 10.1016/S0140-6736(88)92684-0 PMID: 2900943
  114. Xu J, Raff TC, Muallem NS, Neubert AG. Hydrops fetalis secondary to parvovirus B19 infections. J Am Board Fam Med 2003; 16(1): 63-8. doi: 10.3122/jabfm.16.1.63 PMID: 12583652
  115. Enders M, Weidner A, Zoellner I, Searle K, Enders G. Fetal morbidity and mortality after acute human parvovirus B19 infection in pregnancy: Prospective evaluation of 1018 cases. Prenat Diagn 2004; 24(7): 513-8. doi: 10.1002/pd.940 PMID: 15300741
  116. Riipinen A, Väisänen E, Nuutila M, et al. Parvovirus b19 infection in fetal deaths. Clin Infect Dis 2008; 47(12): 1519-25. doi: 10.1086/593190 PMID: 18991512
  117. Barton LL, Lax D, Shehab ZM, Keith JC. Congenital cardiomyopathy associated with human parvovirus B19 infection. Am Heart J 1997; 133(1): 131-3. doi: 10.1016/S0002-8703(97)70259-X PMID: 9006302
  118. Bascietto F, Liberati M, Murgano D, et al. Outcome of fetuses with congenital parvovirus B19 infection: Systematic review and meta-analysis. Ultrasound Obstet Gynecol 2018; 52(5): 569-76. doi: 10.1002/uog.19092 PMID: 29785793
  119. De Jong EP, Lindenburg IT, van Klink JM, et al. Intrauterine transfusion for parvovirus B19 infection: Long-term neurodevelopmental outcome. Am J Obstet Gynecol 2012; 206(3): 204.e1-5. doi: 10.1016/j.ajog.2011.12.035 PMID: 22381602
  120. Katz V, McCoy M, Kuller J, Hansen W. An association between fetal parvovirus B19 infection and fetal anomalies: A report of two cases. Am J Perinatol 1996; 13(1): 43-5. doi: 10.1055/s-2007-994201 PMID: 8645385
  121. Tiessen RG, van Elsacker-Niele AMW, Vermeij-Keers C, Oepkes D, van Roosmalen J, Gorsira MCB. A fetus with a parvovirus B19 infection and congenital anomalies. Prenat Diagn 1994; 14(3): 173-6. doi: 10.1002/pd.1970140305 PMID: 8052564
  122. Weiland HT, Vermey-Keers C, Salimans MMM, Fleuren GJ, Verwey RA, Anderson MJ. Parvovirus B19 associated with fetal abnormality. Lancet 1987; 329(8534): 682-3. doi: 10.1016/S0140-6736(87)90442-9 PMID: 2882099
  123. Ergaz Z, Ornoy A. Parvovirus B19 in pregnancy. Reprod Toxicol 2006; 21(4): 421-35. doi: 10.1016/j.reprotox.2005.01.006 PMID: 16580942
  124. Kinney JS, Anderson LJ, Farrar J, et al. Risk of adverse outcomes of pregnancy after human parvovirus B19 infection. J Infect Dis 1988; 157(4): 663-7. doi: 10.1093/infdis/157.4.663 PMID: 2831283
  125. Miller E, Fairley CK, Cohen BJ, Seng C. Immediate and long term outcome of human parvovirus B19 infection in pregnancy. BJOG 1998; 105(2): 174-8. doi: 10.1111/j.1471-0528.1998.tb10048.x PMID: 9501782
  126. Leung KKY, Hon KL, Yeung A, Leung AKC, Man E. Congenital infections in Hong Kong: An overview of TORCH. Hong Kong Med J 2020; 26(2): 127-38. doi: 10.12809/hkmj198287 PMID: 32245914
  127. Hon KL, Leung KKY, Leung AKC, Man E, Ip P. Congenital infections in Hong Kong: Beyond TORCH. Hong Kong Med J 2020; 26(4): 318-22. doi: 10.12809/hkmj208398 PMID: 32705996
  128. Revilla Grande AI, Carro García T, Sánchez de Dios M, Galán Calvo MJ, Nebreda Mayoral T. Outbreak of infectious erythema at a urban health center. Aten Primaria 2000; 26(3): 172-5. doi: 10.1016/S0212-6567(00)78636-7 PMID: 10996951

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2024 Bentham Science Publishers